Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)

Phase 1

Boehringer Ingelheim

Dabigatran